

HB 1327 -- EMERGING ISSUES IN CANCER MEDICATION

SPONSOR: Solon

This bill prohibits a health benefit plan that provides coverage for cancer chemotherapy treatment from charging a higher co-payment, deductible, or coinsurance amount to a patient for a prescribed orally administered anticancer medication than the amount the plan charges for an intravenously administered or injected cancer medication, regardless of the formulation or benefit category determination by the plan. A health insurance carrier cannot comply with this requirement by increasing the co-payment, deductible, or coinsurance amount for an intravenously administered or injected cancer medication covered under the plan.